<DOC>
	<DOCNO>NCT00620503</DOCNO>
	<brief_summary>This open-label , randomize , single-center , outpatient , unblinded , single-dose , three-way crossover study safety PK property Proellex速 woman age 18 - 34 year . Twelve female subject receive single dose Proellex速 : 25 mg ( fed state , formulation A ) , 25 mg ( fed state , formulation B ) , 25 mg ( fast state , formulation B ) ; successive dosing separate least one week interval previous dose . Blood collect prior take dose , follow dose 24 hour post-dose . Subjects discharge study last blood sample obtain third dose Proellex速 . Safety assess throughout study .</brief_summary>
	<brief_title>Proellex速 Pharmacokinetic Bridging Study II</brief_title>
	<detailed_description />
	<criteria>Subject must able speak , read understand English willing able provide write informed consent Institutional Review Board ( IRB ) approve form prior initiation study procedure . Subject must sign date write Informed Consent Form ( ICF ) undergo study related activity , include discontinuation prohibit medication Premenopausal woman age 18 34 inclusive body mass index 18 35 inclusive Women childbearing potential must willing use effective nonhormonal , doublebarrier method contraception study period minimum 30 day discontinuation study medication . Women hysterectomy allow study Must negative urine pregnancy test screen Able swallow gelatin capsule In general good health Must agree attempt become pregnant time study participation 30 day thereafter Must use tobacco ( nicotine product ) least two year study start Must normal ( abnormal clinically insignificant ) laboratory value screen Willing remain clinic screen visit treatment visit Available treatment followup visit Willing comply study procedures Additional inclusion criterion may apply Pregnant lactate female woman attempt expect become pregnant time study Past present history experience allergic reaction formulation administer study , opinion Principal Investigator , suggest increase potential adverse hypersensitivity Any medical condition , , judgment Principal Investigator , prevent subject start and/or complete study Past present history significant cardiovascular , renal , hepatic disease , thrombophlebitis , thromboembolic disorder , cerebrovascular accident require ongoing medical therapy clinical intervention A QTc interval &gt; 450ms screen Subject abnormal screening visit vital sign clinical laboratory evaluation consider clinically significant Principal Investigator Subjects symptomatic uterine fibroid endometriosis Use oral contraceptive hormonal treatment within 30 day first dose study medication Use hormonereleasing intrauterine device Subject history alcohol and/or drug abuse Known active infection HIV , Hepatitis A , B C Subject participate clinical trial investigational medication within 30 day prior study medication administration plan take experimental drug prior end 30 day participation study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>PK</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>